• New monthly sales record in the USA in April 2026
• Group trailing twelve-month sales of US$22.8 million, up 26%
• FY26 sales (excl. China) guidance upgraded to US$22-23 million

Nova Eye Medical Limited (ASX: EYE), a medical technology company committed to advanced ophthalmic treatment technologies and devices, today announces a new monthly sales record in April 2026, exceeding the record set in March 2026. Trailing twelve-month sales (excluding China) at 30 April 2026 were US$21.6 million, up 27% on the prior comparative period. Group trailing twelve-month sales were US$22.8 million, up 26% on the prior comparative period. With two months of FY26 still to run and trading momentum continuing, the Company has upgraded FY26 sales (excluding China) guidance from US$21-22 million to US$22-23 million. The upgrade follows the Company's first reported positive EBITDA from Operations of US$138,000 for Q3 FY26, as disclosed in the Quarterly Activities and Cashflow Report on 29 April 2026. For Q3 FY26, each U.S. sales representative delivered annualised revenue of approximately US$1.6 million on a weighted average basis, with U.S. sales growing at a compound quarterly rate of approximately 6% over the last six quarters. April sales in the U.S. exceeded the record set in March 2026, further extending the trend. Trading conditions across the U.S. interventional glaucoma sector remain supportive.

FY26 sales revenue (excl. China) of between US$22 million and US$23 million (A$31.4 million to A$32.8 million assuming FX of AUD1.00 = USD0.70 in the last quarter).